The clinical findings showed a 29.6% average improvement from baseline at week 24, with statistically significant results emerging by day 64. For participants presenting with more extensive disease at the onset of the trial, the therapeutic impact was more pronounced, reaching an average improvement of 43.2%. Notably, over half of these specific patients achieved at least a 50% improvement by the end of the study period.

Forte Biosciences characterized the safety profile of FB102 as mild to moderate, noting that it compared favorably against the placebo group. The drug functions as a monoclonal antibody designed to block CD122, a mechanism that modulates IL-2 and IL-15-dependent T-cell activity while preserving regulatory T cells. With this latest rally, the company's stock has more than doubled over the past twelve months.